Dynavax Technologies reported $113.99M in Sales Revenues for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US $ 13538M 1348M
Adma Biologics ADMA:US $ 29.1M 2.72M
Agenus AGEN:US $ 25.94M 5.68M
Amgen AMGN:US $ 6238M 608M
AstraZeneca AZN:LN 11390M 621M
Astrazeneca AZN:US $ 11390M 621M
Biogen BIIB:US $ 2531.8M 202M
Biomarin Pharmaceutical BMRN:US $ 519.36M 69.55M
Bristol Myers Squibb BMY:US $ 11648M 337M
Chimerix CMRX:US $ 0.02M 0.03M
Dynavax Technologies DVAX:US $ 113.99M 81.08M
Gilead Sciences GILD:US $ 6590M 654M
Glaxosmithkline GSK:US $ 9780M 253M
Merk MRK:US $ 15901M 2380M
Nektar Therapeutics NKTR:US $ 24.82M 0.19M
Neurocrine Biosciences NBIX:US $ 310.6M 1.4M
Novartis NOVN:VX SF 12814M 708M
Pfizer PFE:US $ 25661M 2026M
Regeneron Pharmaceuticals REGN:US $ 2965.1M 1986.6M
Roche Holding ROG:VX 16.44B 474M
Sarepta Therapeutics SRPT:US $ 210.83M 9.37M
Tg Therapeutics TGTX:US $ 2.02M 0.3M
Vertex Pharmaceuticals VRTX:US $ 2097.5M 24.94M